Segment, Geographical and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting Information, Operating Income (Loss) [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):



	Year Ended December 31, 2018							Year Ended December 31, 2017
	Performance Enzymes		Novel Biotherapeutics		Total			Performance Enzymes		Novel Biotherapeutics			Total
Revenues:
Product revenue	$	25,590	$	—	$	25,590		$	26,685	$	—		$	26,685
Research and development revenue	21,483		13,521		35,004			15,648		7,691			23,339
Total revenues	47,073		13,521		60,594			42,333		7,691			50,024
Costs and operating expenses:
Cost of product revenue	12,620		—		12,620			14,327		—			14,327
Research and development⁽¹⁾	18,924		10,185		29,109			16,847		12,107			28,954
Selling, general and administrative	7,538		771		8,309			7,371		—			7,371
Total segment costs and operating expenses	39,082		10,956		50,038			38,545		12,107			50,652
Income (loss) from operations	$	7,991	$	2,565	$	10,556		$	3,788	$	(4,416	)	$	(628	)
Corporate costs⁽²⁾					(20,324		)						(21,245		)
Depreciation					(1,147		)						(1,042		)
Loss before income taxes					$	(10,915	)						$	(22,915	)

⁽¹⁾Research and development expenses and Selling, general and administrative expenses exclude depreciation.

⁽²⁾Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):



	2018						2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	2,591	$	338	$	2,929	$	2,306	$	208	$	2,514

Schedules of Concentration of Risk

Customers that each contributed 10% or more of our total revenues were as follows:



	Percentage of Total Revenues For The Years Ended December 31,
	2018		2017		2016
Merck	29	%	28	%	47	%
Nestlé Health Science	22	%	15	%	*
Tate & Lyle	13	%	11	%	*
Novartis	*		14	%	*
GSK	*		*		22	%

Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:



	Percentage of Accounts Receivables As Of December 31,
	2018		2017
Merck	37	%	31	%
Nestlé Health Science	17	%	*
Tate & Lyle	*		16	%
Novartis	11	%	15	%
Kyorin Pharmaceutical Co Ltd	16	%	*
Exela PharmaSci, Inc.	*		14	%

* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):



	Year Ended December 31,
	2018		2017		2016
Revenues
Americas	$	15,370	$	15,575	$	23,126
EMEA	22,361		19,610		17,138
APAC	22,863		14,839		8,573
Total revenues	$	60,594	$	50,024	$	48,837

Schedule of Long-lived Assets by Geographical Area

Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):



	December 31,
	2018		2017
Long-lived assets
United States	$	4,759	$	2,815

Schedule of Goodwill



	December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total

Goodwill	$	2,463	$	778	$	3,241